Nov 2026· Analytical Chemistry· 0 citations· 39 references
TL;DR
It is demonstrated that biotin modification enhances both tumor accumulation and retention, enabling sensitive, long-lasting NTR imaging and offers a reliable tool for real-time NTR monitoring with clear advantages in sensitivity, selectivity, and translational feasibility.
Abstract
Tumor hypoxia-associated nitroreductase (NTR) is a promising biomarker for cancer diagnosis, yet conventional probes often lack active tumor targeting and sustained retention. Herein, we developed a biotin-functionalized near-infrared fluorescent probe, DHX-Bio-NO2, for dual-recognition tumor imaging via biotin receptor recognition and NTR activation. The probe shows a 48-fold fluorescence turn-on at 715 nm upon NTR reduction, with a detection limit of 12.8 ng/mL, excellent selectivity over interferents, and stable performance at pH 3−9. Cellular imaging studies confirm that biotin mediates active uptake, while hypoxia-induced NTR upregulation triggers strong fluorescence, which is suppressed by the inhibitor dicoumarol. Probe DHX-Bio-NO2 also can clearly distinguish cancer cells (HeLa, A549, HepG2) from normal BEAS-2B cells. In vivo, intravenous injection into 4T1 tumor-bearing mice produces bright, tumor-specific fluorescence that persists for 24 h, whereas a biotin-free control shows weak and rapidly fading signals. Ex vivo imaging verifies predominant accumulation in tumor tissues with minimal organ background. These results demonstrate that biotin modification enhances both tumor accumulation and retention, enabling sensitive, long-lasting NTR imaging. The probe offers a reliable tool for real-time NTR monitoring with clear advantages in sensitivity, selectivity, and translational feasibility.
Nitroreductase (NTR), overexpressed in solid tumors, is a specific biomarker indicating tumor hypoxia. NTR-activatable photosensitizers are an effective approach for tumor theranostics. However, challenges such as slow response, imprecise tumor recognition, and weak photodynamic effects under hypoxic conditions limit...
Findings provide proof-of-concept support for further evaluation of activatable AS1411-based probes for molecular imaging of nucleolin-overexpressing TNBC and enable preferential, high-contrast fluorescence imaging in the tested MDA-MB-231 TNBC model across in vitro, in vivo, and ex vivo experiments.
Jun-Tao Tan, Zi-Xi Hu, Da Huang et al.· Frontiers in Bioengineering...· 0 citations
Intraoperative fluorescence imaging holds great promise for achieving complete cytoreduction in ovarian cancer, but its clinical utility is currently constrained by the limitations of existing imaging agents. In particular, the leading clinical probe, OTL38, operates in the near-infrared I (NIR-I; 700 to 1000 nanometer...
Wan-Ying Li, Zi-Mu Yuan, Shi-Qi Bai et al.· Science Advances· 0 citations
Fluorescence-guided surgery requires tumor-imaging probes that provide reliable contrast while minimizing background interference. Herein, we developed a gastrin-releasing peptide receptor (GRPR)-targeted near-infrared (NIR) fluorescent probe, IR783-BBN, by covalently conjugating the bombesin peptide with the IR783 flu...
Abnormal pH and viscosity are defining features of the tumor microenvironment, offering valuable targets for cancer diagnostics and therapy. Here, we introduce Cy7-TCF-Mpip, a triple-functional near-infrared (NIR) probe that integrates pH responsiveness, viscosity sensitivity, and photodynamic activity within a single...
Charupong Saengboonmee, Pitchaya Amornkittithaworn, O. Khaikate et al.· ACS Applied Bio Materials· 0 citations
Traditional small-molecule fluorescent probes suffer from nonspecific accumulation in metabolic organs, limiting their application in lung disease monitoring. Herein, we developed a fluorine-substituted dicyanoisophorone-based probe (PFCu) with picolinate as the Cu2+-recognition moiety. PFCu preferentially illuminate...
Jin-Ping Shao, Xiao-Tong An, Cong Zhang et al.· Journal of Medicinal Chemist...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.